Economic Evaluation of Palliative Management versus Peritoneal Dialysis and Hemodialysis for End-Stage Renal Disease: Evidence for Coverage Decisions in Thailand Yot Teerawattananon1 Miranda Mugford2 Viroj Tangcharoensathien1 1Ministry of Public Health, Nonthaburi, Thailand 2University of E

This study aims to determine the cost-effectiveness and cost-utility of medical rehabilitation services for inpatients suffering from a stroke. It will compare the outcome of medical rehabilitation services in terms of functional status and quality of life before and after service providing. Moreover, it will compare cost-effectiveness and cost-uti

The aims of this study were 1) to estimate the incremental cost-effectiveness ratio (ICER) of offering statins for primary prevention of CVD for each CVD risk group, and 2) to estimate the budget impact if the statins were prescribed to those people living with different CVD risks. This was a model-based economic evaluation. A Markov model was cons

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Waranya Rattanavipapong1, Tanunya Koopitakkajorn1, Naiyana Praditsitthikorn1,2,*, Surakameth Mahasirimongkol3 andYot Teerawattananon1 Summary Purpose There is strong evidence o

Economic evaluation of HLA-B*1502 screening for preventing carbamazepine- induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is prioritized by stakeholders under ‘Research for development of health benefit package under universal coverage scheme’. The study carried out an evidence to inform the Subcommittee for Developm

The introduction of Coronavirus disease 2019 (COVID-19) vaccines urged all Thais to seek prevention of serious illness and death from COVID-19. However, immunocompromised individuals might not be able to achieve an efficient immune response from these vaccines. This study aimed to evaluate the cost-

The objective of this study is to determine the economic evaluation of the treatment of chronic hepatitis B by using drugs that are currently available in Thailand, and to analyze the budget impact in listing drugs with cleared health economic evaluation into the National List of Essential Medicines.  01-340-2552

In Thailand, the prevalence of chronic kidney disease (CKD) is 17.5% of the population (Ingsathit et al., 2010). According to Thailand’s National Health Security Office (2021), in each year, this public health agency spends approximately 10,000 million Baht in renal dialysis and 1,000 million Baht for the CKD treatment and other related expenses.